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Inhibition of E-Selectin (GMI-1271) or E-
selectin together with CXCR4 (GMI-1359)
re-sensitizes multiple myeloma to therapy
Barbara Muz1, Feda Azab1, Mark Fiala2, Justin King2, Daniel Kohnen2, William E. Fogler3, Ted Smith3, John L. Magnani3,
Ravi Vij2 and Abdel Kareem Azab1
Dear Editor,
Multiple myeloma (MM) is a plasma cell malignancy
localized in the bone marrow (BM) characterized by
continuous metastasis. MM remains incurable, despite
the improved overall survival of MM patients due to
clinically introduced novel treatments such as proteasome
inhibitors (bortezomib and carfilzomib) and immuno-
modulatory drugs (IMiDs; lenalidomide)1.
The complex cross-talk between MM cells and the
tumor microenvironment (TME) facilitates tumor pro-
gression and therapy resistance2. Adhesion molecules
such as selectins3,4 and C-X-C chemokine receptor type 4
(CXCR4, CD184)5–7 play pivotal roles in advancement of
MM, suggesting that these molecules could be targeted to
reduce metastasis and overcome drug resistance. Elevated
CXCR4 expression enables MM cells’ dissemination from
the primary tumor site to the peripheral blood (PB) and
further to a new BM site attracted by chemokines such as
stromal-derived growth factor-1 (SDF-1). Homing of MM
is initiated through interaction between ligands present
on MM cells such as cutaneous lymphocyte-associated
antigen (CLA; role of which is not well described in
MM)3,8 and adhesion molecules E- and P-selectin
expressed on vascular endothelium, which induce roll-
ing, adhesion, and extravasation. Most of cancer therapies
consist of targeting the MM cells directly; however,
recently disrupting MM interactions with the TME
through inhibiting adhesion of cancer cells to the TME or
hindering the homing of already circulating tumor cells
thus preventing metastasis have been suggested as ther-
apeutic strategies3–5,7,8. In this study, we tested the effect
of blocking E-selectin alone using GMI-12718 and
blocking both E-selectin and CXCR4 using GMI-13599 on
TME disruption in order to sensitize MM cells to
chemotherapy.
First, analysis of CXCR4, CLA, and E-selectin mRNA
expression in CD138+ plasma cells isolated from newly
diagnosed MM patients using the Gene Expression Omni-
bus database10 showed (mean ± s.e.m.) 18,223.19 ± 452.04,
3472.67 ± 118.01, and 42.16 ± 2.01, respectively (Fig. 1a).
Interestingly, CLA expression in CD138+ plasma cells was
the highest among patients with MM (3472.67 ± 118.01)
compared to monoclonal gammopathy of undetermined
significance (2459.96 ± 270.13) and healthy donors
(1910.85 ± 107.72) (Fig. 1b). This data suggests that CXCR4
mRNA is highly expressed in newly diagnosed MM patients
and that CLAmRNA expression significantly increases with
MM advancement. We have previously demonstrated that
MM progression and dissemination was hypoxia depen-
dent, and hypoxic MM cells had improved cell trafficking6,
increased tumor initiation, and induced drug resistance
contributing to minimal residual disease and relapse7,11.
Natoni et al. demonstrated that the CLA was increased in
hypoxic MM cells implying disease progression, and CLA
expression was further augmented in MM cells from
relapsed/refractory patients compared to newly diagnosed
patients8. These results suggest that CLA undergoes
dynamic changes with MM development and could
potentially be a biomarker of disease progression and drug
resistance. However, we found that CLA expression was
negligible and restricted to a small subpopulation of MM
cells (1.3% MM.1S, 0.9% H929 and 6.3% U266) (Fig. 1c)
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possibly due to lack of TME and hypoxic conditions. In all,
85% of MM.1S, 44% of H929, and 97% of U266 cells were
positive for CXCR4 (Fig. 1c), with the relative mean fluor-
escent intensity (RMFI) of 5.8, 10.6, and 12.9, respectively
(Fig. 1d). Regarding MM-supporting cells, 96% of human
umbilical vein endothelial cells (HUVECs), 70% of MSP-1,
and 80% of HS-5 cells were E-selectin positive (Fig. 1e) with
an RMFI of 25, 12, and 17, respectively (Fig. 1f). These cells
had insignificant levels of CLA; however, CXCR4 was pre-
sent in HUVECs, MSP-1, and HS-5 at 57, 55, and 29% of
Fig. 1 CXCR4 mRNA is highly expressed in primary multiple myeloma (MM) cells, CLA expression increases with myeloma progression;
CXCR4 protein expression is widely present in MM cells, while E-selectin protein is highly expressed in endothelial cells and stromal cells.
Gene expression of E-selectin (ID 206211_at), CLA (ID 209879_at), and CXCR4 (ID 217028_at) mRNA analyzed in CD138+ bone marrow plasma cells
isolated from newly diagnosed MM patients (n= 559) using the Gene Expression Omnibus database [log scale] (a). The expression of CLA mRNA in
CD138+ plasma cells harvested from healthy donors (n= 22), MGUS patients (n= 44), and newly diagnosed MM patients (n= 559) using the Gene
Expression Omnibus database [log scale] analyzed using one-way analysis of variance test (b). Percentage of CLA+- and CXCR4+-positive cells in MM
cell lines demonstrated as mean ± s.e.m (c). CLA and C-X-C chemokine receptor type 4 (CXCR4) protein expression levels in MM cell lines
demonstrated as RMFI (mean ± s.e.m.). Results are obtained from three independent biological replicates and repeated minimum in three separate
experiments (d). Expression of cell surface proteins including E-selectin, CLA, and CXCR4 in endothelial cells (human umbilical vein endothelial cells),
malignant stromal cells (MSP-1), and normal stromal cells (HS-5) demonstrated as the percentage of positive cells (e) and RMFI (f). Results are
representative of at least three independent experiments and demonstrated as mean ± s.e.m. CLA cutaneous lymphocyte-associated antigen, MGUS
monoclonal gammopathy of undetermined significance, RMFI relative mean fluorescent intensity
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cells, respectively (Fig. 1e), with an RMFI of 6, 3.5, and 2.9,
respectively (Fig. 1f), confirming high expression of E-
selectin and CXCR4 in endothelial and stromal cells.
Next, we tested the effect of GMI-1271 (E-selectin
antagonist) and GMI-1359 (E-selectin and CXCR4 dual
antagonist) on the ability of MM cells to migrate to
conditioned media. Pretreatment of MM.1S cells with
GMI-1271 significantly reduced chemotaxis to HS-5 and
MSP-1 media by ≤20%, while GMI-1359 greatly reduced
chemotaxis to SDF-1-enriched-, HS-5-, and MSP-1-
derived media by 47, 53, and 61%, respectively (Fig. 2a).
U266, but not MM.1S and H929, cell adhesion to
HUVECs was significantly reduced following GMI-1271
treatment, possibly due to the highest percentage of CLA-
positive cells, while GMI-1359 treatment significantly
decreased adhesion of MM.1S, H929, and U266 to
HUVECs by 38, 53, and 42%, respectively (Fig. 2b). Fur-
thermore, in order to recapitulate the MM extravasation
through the endothelium to the BM, we performed a
trans-endothelial migration in vitro, where labeled MM
cells were added on top of HUVECs and trans-migrated
toward stromal cells cultured at the bottom of a Boyden
chamber. MM cells cultured overnight in hypoxia, which
was shown to increase CXCR46 and CLA8 expression,
decreased the hypoxia-induced trans-endothelial migra-
tion of MM cells to stroma when pretreated with GMI-
1271 or GMI-1359 by 17% and 40%, respectively (Fig. 2c).
Similarly, GMI-1359 pretreatment caused a significant
MM.1S cell retention in the circulation and prevented
extravasation at 90 min postintravenous injection in vivo
(Fig. 2d). Since GMI-1359 blocks not only CXCR4 but
also E-selectin, we performed an experiment where either
MM cells or mouse endothelium or both were pretreated
with GMI-1359 before monitoring MM homing to the
BM (Fig. 2e). When mice were injected with GMI-1359
intravenously 30 min prior to the injection of labeled MM
cells, homing of the MM cells was inhibited by ~40%
compared to vehicle-treated mice. Moreover, when the
cells were pretreated with GMI-1359 prior injection, their
homing to the BM was almost completely abrogated,
regardless whether the mice endothelium was pretreated
with GMI-1359 or not. Interestingly, U266 homed the
least compared to MM.1S and H929.
Next, we examined the effect of GMI-1271 in com-
bination with lenalidomide on MM.1S survival cultured
with or without MSP-1 stromal cells in vitro. We found
that GMI-1271 alone did not affect MM.1S survival, and
co-culture with stroma significantly induced drug
resistance to lenalidomide, while combination treatment
with both drugs significantly overcame the stroma-
induced lenalidomide resistance (Fig. 2f). Similar results
were observed for H929 survival co-cultured with
HUVECs (Supplementary Fig. 1A). Consequently, we
tested MM tumor progression in a human xenograft
mouse model, where SCID mice were inoculated with
MM.1S-Luc and tumor progression was monitored
using bioluminescent imaging. GMI-1271 and lenali-
domide as single agents delayed tumor growth by 40%
and 35%, respectively, while combined lenalidomide and
GMI-1271 significantly delayed tumor growth by 55%
and 64% at days 14 and 21, respectively, compared to
vehicle (Fig. 2g). Next, we tested GMI-1271 in combi-
nation with carfilzomib (CFZ) on MM.1S survival
in vitro, which significantly overcame the stroma-
induced CFZ resistance (Fig. 2h). Similar results were
obtained for H929 and U266 co-cultured with stroma,
treated with GMI-1271 in combination with CFZ and
bortezomib (BTZ) (Supplementary Fig. 1). Subse-
quently, we examined mice survival using a syngeneic
5TGM1 disseminated mouse model and demonstrated
significantly extended median survival in groups treated
with vehicle, GMI-1271, CFZ, or combination, which
were 36.5, 36.5, 40, and 49.5 days, respectively (Fig. 2i).
Next, combination treatment with GMI-1359 and CFZ
studied in vitro demonstrated that GMI-1359 sig-
nificantly overcame the stroma-induced resistance to
CFZ (Fig. 2j). Similar results were obtained for H929 and
U266 co-cultured with stroma and treated with GMI-
1359 in combination with CFZ or BTZ (Supplementary
Fig. 2), as well as using a three-dimensional tissue-
engineered bone marrow with MM.1S co-cultured with
accessory cells recapitulating TME (Supplementary Fig.
3). Subsequently, median survival of mice inoculated
with 5TGM1 cells treated with vehicle, GMI-1359, CFZ,
or combination was significantly extended to 32.5, 34,
38.5, and 49 days, respectively (Fig. 2k). These results
imply that E-selectin and/or CXCR4 antagonists (GMI-
1271 and GMI-1359) were sufficient in retaining MM
cells in the circulation, inferring longer MM exposure to
chemotherapies and improved MM response to pro-
teasome inhibitors and IMiDs. Our results are in
agreement with others showing that both GMI-1271 and
GMI-1359 disrupted the TME and mobilized cancer
cells into the circulation more effectively and gradually
over long periods of time compared to CXCR4 inhibi-
tion alone (using Plerixafor)8,12–14. Again, sustaining the
presence of tumor cells in the blood by inhibiting their
re-entry into the BM provides a longer window to target
these cells in the circulation.
In conclusion, majority of MM patients relapse and
become refractory to therapy, due to the supportive TME
that assists cancer with drug resistance and metastasis1,2.
Herein, we disrupted the interaction between MM cells
and the TME with GMI-1271 and GMI-1359 by
decreasing CXCR4 and E-selectin-mediated adhesion and
chemotaxis of MM cells, which sensitized them to therapy
in vitro, and by inhibiting the homing process thus
extending the exposure of MM cells to chemotherapies
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Fig. 2 (See legend on next page.)
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and improving mice survival in vivo. These results provide
preclinical basis for future clinical trials to test the ability
of dual inhibition of E-selectin and CXCR4 to sensitize
relapsed/refractory MM patients to therapy. Notably, a
completed Phase 1/2 clinical trial in acute myeloid leu-
kemia patients using GMI-1271 showed high remission
rates and improved overall survival with favorable
safety15, and a Phase 1 clinical trial is being performed on
MM patients (NCT02811822). Currently, GMI-1359 is
being evaluated in a Phase 1 clinical trial in healthy
volunteers (NCT02931214).
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